← back to search

Barbara Hunt

Takeda (United States) ·
Area of research
Gastroenterology · Surgery
Research interest
Research interests include Gastroesophageal reflux and treatments, Gout, Hyperuricemia, Uric Acid, Helicobacter pylori-related gastroenterology studies, and Eosinophilic Esophagitis.
h-index
30
citations
4,118
works
90
NIH funding
primary concept
Medicine
email

Recent publications

Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
Randomised clinical trial: Efficacy and safety of <scp>on‐demand</scp> vonoprazan versus placebo for non‐erosive reflux disease
Alimentary Pharmacology & Therapeutics 2023cited by 37position: middledoi
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial
Gastroenterology 2022cited by 139position: middledoi
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
Arthritis & Rheumatology 2022cited by 23position: middledoi
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
New England Journal of Medicine 2018cited by 884position: middledoi
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
Arthritis Research & Therapy 2018cited by 31position: middledoi
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase <scp>III</scp> Placebo‐Controlled Study
Arthritis & Rheumatology 2018cited by 30position: middledoi
Effects of Febuxostat in Early Gout
Arthritis & Rheumatology 2017cited by 90position: middledoi
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study
Journal of the American Heart Association 2017cited by 75position: middledoi
Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal Impairment
Arthritis & Rheumatology 2016cited by 124position: middledoi
Diabetes and gout: efficacy and safety of febuxostat and allopurinol
Diabetes Obesity and Metabolism 2013cited by 37position: middledoi
CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
American Heart Journal 2012cited by 59position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Lhanoo Gunawardhana · Takeda (United States)7 papers (2016–2022)Kenneth G. Saag · University of Alabama System6 papers (2016–2022)Andrew Whelton · Johns Hopkins University6 papers (2016–2022)Majin Castillo · Takeda (United States)4 papers (2018–2022)William B. White · University of Connecticut3 papers (2012–2022)Patricia MacDonald · McGill University Health Centre2 papers (2016–2017)Loren Laine · Yale University2 papers (2022–2024)Philip B. Gorelick · Northwestern University2 papers (2018–2022)Ronnie Fass · University of Arizona2 papers (2023–2024)Rena Yadlapati · Brigham and Women's Hospital2 papers (2023–2024)Stuart J. Spechler · Baylor University Medical Center2 papers (2022–2024) · 2 papers (2023–2024) · 2 papers (2023–2024)Robert L. Jackson · University of Missouri2 papers (2012–2013)Philip O. Katz · Weill Cornell Medicine2 papers (2022–2024)Jeffrey Borer · Valve (United States)2 papers (2018–2022)Tom M. Harris · National Laboratory of the Rockies2 papers (2023–2024) · 1 papers (2012–2012)Saima Chohan · Arthritis and Rheumatism Associates1 papers (2012–2012) · 1 papers (2017–2017)